Isofol Medical reported positive results from 20 more patients enrolled in the ongoing phase I/IIa study in metastatic colorectal cancer (mCRC). While the sample size was limited and the treatment period relatively short, results indicate a clinical benefit in line with expectations. We will return with an updated analysis in the upcoming days.